Last updated on March 2018

Tumor Registry Pancreatic Cancer

Brief description of study

The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.

Clinical Study Identifier: NCT02089269

Contact Investigators or Research Sites near you

Start Over

David Hamm, Dr.

Freiburg, Germany
  Connect »